Y-mAbs Therapeutics, Inc. (YMAB) Financials
YMAB Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 127.9 million | 26.9 million |
2023-09-30 | 128.9 million | 28.7 million |
2023-06-30 | 132.4 million | 27.7 million |
2023-03-31 | 137.4 million | 29.6 million |
YMAB Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -8.0 million | 3.1 million |
2023-09-30 | -1.3 million | 2.4 million |
2023-06-30 | -4.7 million | 3.6 million |
2023-03-31 | -13.1 million | 5.3 million |
YMAB Net Income
No data available :(
YMAB Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 78.6 million | - | 1.4 million |
2023-09-30 | 86.6 million | - | 1.6 million |
2023-06-30 | 87.9 million | - | 1.2 million |
2023-03-31 | 92.6 million | - | 1.5 million |
YMAB Shares Outstanding
YMAB Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | - | 13.4 million | 11.1 million | - |
2023-09-30 | - | 15.4 million | 10.2 million | - |
2023-06-30 | - | 12.1 million | 11.3 million | - |
2023-03-31 | - | 13.4 million | 12.3 million | - |
YMAB Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 23.4 million | 2.0 million |
2023-09-30 | 20.5 million | 2.6 million |
2023-06-30 | 20.8 million | 4.6 million |
2023-03-31 | 20.3 million | 2.1 million |
YMAB
Price: $17.28
52 week price:
Earnings Per Share: -0.49 USD
P/E Ratio: -29.09
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 294900
Market Capitalization: 629.1 million